-
Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief
•
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as its executive vice president of global drug development and chief medical officer (CMO). Dr. Germa will report directly to CEO Dr. Qian Xueming. Role and ResponsibilitiesDr. Germa will lead the global development and translational research…
-
NHC Issues Notification on Medication Safety Management and Rational Drug Use
•
The National Healthcare Commission (NHC) has released a notification focusing on medication safety management and rational drug use. The notice outlines measures to enhance medication safety and promote rational drug use in medical institutions. Key Measures Evaluation and AssessmentThe management of drug safety will be included as part of the…
-
Ningbo Health Gene Raises Hundreds of Millions in Series C Financing
•
Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round led by SCGC. Other investors included BioTrack Capital, Hefeng Venture Capital, Yingong Venture Capital, and Binjiang Xincheng Development Investment. The proceeds will be directed…
-
Intuitive Surgical-Fosun JV Breaks Ground on Shanghai Medical Robot Base
•
Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture (JV) between China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and US firm Intuitive Surgical, Inc, has commenced construction on a 2.08-hectare headquarters and industrialization base. The medical robot manufacturing R & D center is situated in Zhangjiang Hi-Tech…
-
Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures
•
Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a global sales growth of 9.6% year-on-year (YOY) in constant exchange rate terms to EUR12.8 billion (USD13 billion). The growth was driven by strong performances in the Pharmaceuticals and Consumer Health segments. Pharmaceuticals and Consumer HealthIn…
-
Intellective Biologics Raises Over RMB500m in Series C Financing Round
•
China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly raised over RMB500 million (USD74.1 million) in a Series C financing round. The round was co-led by Tsing Song Capital and Gaorong Capital, with participation from Fuho Capital, CNCB Investment, Founder Securities, and Win Harbor…
-
MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of 130 million shares priced at RMB8.16 (USD1.21) per share on Shanghai’s Sci-Tech Innovation Board (STAR). With 655 million shares issued, the IPO will bring in RMB1.06 billion (USD157 million) for MicuRx. Product PipelineMicuRx’s MRX-I (contezolid),…
-
invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19
•
invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that its tender offer for all outstanding shares of UK bispecific antibody specialist F-star Therapeutics Inc. (Nasdaq: FSTX) has been extended. The existing offer of USD7.12 per share remains unchanged, representing a total deal value of…
